Trial Profile

A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Prexigebersen (Primary) ; Paclitaxel
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; Glandular and epithelial neoplasms; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Uterine cancer
Focus Adverse reactions; First in man
Sponsors Bio-Path Holdings

Most Recent Events

07 Mar 2025 Planned End Date changed from 1 Oct 2024 to 1 Oct 2027.
07 Mar 2025 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2027.
10 Jan 2025 According to a Bio-Path Holdings media release, completion of the second and third dosing cohorts are expected in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com